Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) Non Operating Investment Income: 2018-2021

Historic Non Operating Investment Income for Lineage Cell Therapeutics (LCTX) over the last 3 years, with Mar 2021 value amounting to $6.0 million.

  • Lineage Cell Therapeutics' Non Operating Investment Income rose 378.86% to $6.0 million in Q1 2021 from the same period last year, while for Mar 2021 it was $9.3 million, marking a year-over-year increase of 361.16%. This contributed to the annual value of $6.0 million for FY2021, which is 32.11% up from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Non Operating Investment Income stood at $6.0 million for Q1 2021, which was up 746.07% from $712,000 recorded in Q4 2020.
  • In the past 5 years, Lineage Cell Therapeutics' Non Operating Investment Income ranged from a high of $6.0 million in Q1 2021 and a low of -$4.5 million during Q3 2019.
  • In the last 3 years, Lineage Cell Therapeutics' Non Operating Investment Income had a median value of $712,000 in 2020 and averaged $854,000.
  • The largest annual percentage gain for Lineage Cell Therapeutics' Non Operating Investment Income in the last 5 years was 798.14% (2019), contrasted with its biggest fall of 19,482.61% (2019).
  • Quarterly analysis of 4 years shows Lineage Cell Therapeutics' Non Operating Investment Income stood at $523,000 in 2018, then slumped by 54.88% to $236,000 in 2019, then spiked by 201.69% to $712,000 in 2020, then soared by 378.86% to $6.0 million in 2021.
  • Its last three reported values are $6.0 million in Q1 2021, $712,000 for Q4 2020, and $120,000 during Q3 2020.